Evidence map›Paper›PMID 28976944›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018

The New News about Lithium: An Underutilized Treatment in the United States.

Robert M Post

Open access · hybridAbstract readReview
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A qualitative exploration of perspectives on taking lithium supplements.Therapeutic advances in psychopharmacology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. What Patients with Bipolar Disorder Need to Know about Lithium.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  8. Review
  9. Lithium: how low can you go?International journal of bipolar disorders · 2024
    Article
  10. Mood and behavior regulation: interaction of lithium and dopaminergic system.Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Review
  11. Article
  12. Article
  13. Lithium and Valproate in Bipolar Disorder: From International Evidence-based Guidelines to Clinical Predictors.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022
    Review
  14. Review
  15. Impact of Lithium on Suicidality in the Veteran Population.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022
    Article
  16. Genetics and Brain Transcriptomics of Completed Suicide.The American journal of psychiatry · 2022
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Robert M PostGeorge Washington University School of Medicine, Bipolar Collaborative Network, Bethesda, MD, USA.
George Washington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lithium use for the treatment of mood disorders remains quite low, particularly in the United States compared with some European countries. Mogens Schou pioneered the study of lithium for prophylaxis of the recurrent mood disorder and encouraged its greater use. In an effort to further address the appropriate role of this drug, the multiple assets of lithium beyond its well-known antimanic effect are reviewed, and a brief summary of its side effects is outlined. It appears that lithium has positive effects in depression and suicide prevention, cognition, and reducing the incidence of dementia. It increases the length of telomeres and has positive effects in prevention of some medical illnesses. Lithium side-effect burden, especially its association with end-stage renal disease, may be less than many have surmised. New data indicate the importance of long-term prophylaxis after a first manic episode to lessen episode recurrence, allow cognition to recover to normal, and prevent various aspects of illness progression. After a first manic episode, 1 year of randomized treatment with lithium was superior to that of quetiapine, suggesting the importance of having lithium in the treatment regimen. Given the highly recurrent and progressive course of bipolar disorder sometimes even in the face of conventional treatment, the role and enhanced use of lithium deserves reconsideration.

Indexed as

Bipolar DisorderCognitionDementiaDepressionHumansLithiumSecondary PreventionSuicide PreventionTelomere HomeostasisUnited StatesLithium

Identifiers

PMID28976944
PMCPMC5854802
OpenAlexW2761346210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.